Introduction
As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled
in the phase III trials of the quadrivalent HPV vaccine.
Materials and methods
German females (n = 437; 9–23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline
characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16–23, abnormal cervical cytology and sexually transmitted
diseases.
Results
Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All
subjects <17 years were naïve to the four vaccine types.
Discussion
The results of the vaccine trials have demonstrated that it is worth administering prophylactic HPV vaccines before sexual
debut; however, none of these sexually active German women were positive to all four types and most were positive to only
one type. Thus, all women had the potential to benefit from vaccination with a quadrivalent HPV vaccine.
Keywords HPV prevalence - Prophylactic quadrivalent HPV vaccine - Cervical cytology -
Chlamydia trachomatis
-
Neisseria gonorrhoeae
- Female
Previously presented at the Joint 2007 Congress of the Bavarian and Austrian Societies for Obstetrics and Gynaecology (BGGF
& OEGGG). May 2007; Abstract # V8–4.